Arrowhead Pharmaceuticals stock analysis
Want to see ARWR full AI Analyst Report?
Arrowhead Pharmaceuticals (ARWR) Stock Price & Analysis
ARWR Stock Chart & Stats
- Day’s Range
- $41.17 - $44.80
- 52-Week Range
- $37.43 - $95.49
- Previous Close
- $43.65
- Volume
- N/A
- Average Volume (3M)
- 2.17M
- Market Cap
- $5.85B
- Enterprise Value
- $9.46B
- Total Cash (Recent Filing)
- $1.19B
- Total Debt (Recent Filing)
- $1.00B
- Price to Earnings (P/E)
- ―
- Beta
- 2.17
- Next Earnings
- Feb 10, 2027 (Est.)
- EPS Estimate
- -1.45
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
REDEMPLO Commercial Traction
Rapid prescription and prescriber growth provides early evidence of demand for REDEMPLO and supports the commercial platform being built around the product. Continued adoption could create a more durable revenue base as payer access expands and physicians gain experience.
Strong Plozasiran Efficacy
Consistent pivotal efficacy across two studies strengthens the case for plozasiran as a differentiated treatment in severe hypertriglyceridemia. The depth of lipid reduction and broad endpoint success could support regulatory approval, physician adoption, and long-term commercial relevance.
Improved Debt Structure
Refinancing materially lowers the stated interest rate versus the retired facility and extends maturity without scheduled amortization. These terms can preserve cash for clinical development and commercialization while reducing near-term repayment pressure, despite continued leverage.
Bears Say
Severe Profitability Deterioration
The sharp move to a large loss shows that operating costs currently overwhelm commercial and licensing revenue. Unless product revenue scales substantially or spending moderates, persistent losses can consume capital, reduce financial flexibility, and delay the path toward sustainable profitability.
Elevated Leverage And Financial Risk
The combination of high debt and a sharply reduced equity base leaves Arrowhead less able to absorb development setbacks or prolonged losses. Elevated leverage can increase refinancing and dilution risk and may constrain capital allocation as the company funds a costly pipeline.
Uncertain SHTG Launch Execution
The expected sHTG launch is not yet assured because approval, labeling, payer interaction, and commercial assumptions remain unresolved. Any delay or restrictive label could postpone meaningful revenue, complicate planning, and leave the company dependent on financing while expenses remain elevated.
Arrowhead Pharmaceuticals News
ARWR FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
What is Arrowhead Pharmaceuticals’s market cap?
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Is Arrowhead Pharmaceuticals overvalued?
Does Arrowhead Pharmaceuticals pay dividends?
What is Arrowhead Pharmaceuticals’s EPS estimate?
How many shares outstanding does Arrowhead Pharmaceuticals have?
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Arrowhead Pharmaceuticals Stock Smart Score
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher R. Anzalone
- Employees
- 1,059
- Website
- arrowheadpharma.com
- Address
- 177 East Colorado Boulevard, Pasadena, CA, 91105, US
Arrowhead Pharmaceuticals (ARWR) Earnings & Revenues
ARWR Earnings Call
Earnings Call SentimentPositive
The call was predominantly optimistic, with strong REDEMPLO prescription and prescriber growth, broadening payer coverage, positive pivotal sHTG efficacy results, clinical validation of new RNAi delivery capabilities and improved financing terms. These positives were tempered by a substantial net loss, lower year-over-year revenue, higher operating expenses, ongoing prescription-to-paid-claim conversion work, regulatory and launch uncertainty for sHTG, glycemic-control findings and unresolved safety and dosing questions for ARO-DIMER-PA.
View all ARWR earnings summariesARWR Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |









